Stage labels are useful only when they compress evidence. “Seed” is not a legal status or self-declared identity. A company can have revenue and still be pre-product-market fit; it can have an MVP with no validated buyer; deep tech may have advanced technical maturity without commercial proof. Build a stage model around what is demonstrated, what remains hypothesis and what type of risk capital the next milestone requires.
Know what weak and strong look like
| Readiness area | Weak / diligence risk | Strong / investor-ready |
|---|---|---|
| Idea/discovery | Problem based on founder belief. | Repeated customer/user evidence confirms painful problem, buyer/user and current alternative. |
| MVP | Product exists. | Smallest usable product tests core value with target users and measurable success criteria. |
| Revenue/validation | One paid project called PMF. | Multiple customers pay for substantially repeatable offer; economics/retention beginning to form. |
| Seed/PMF search | Round label determines stage. | Evidence shows growing repeatability, retention/value and a credible path to scalable acquisition/delivery. |
| Scaling | Team/headcount or funding grew. | Repeatable acquisition/delivery/retention economics support adding capital faster than complexity. |
Use evidence gates, not vanity gates
Website launch, incorporation, app-store approval, press coverage, waitlist and pitch competition wins can matter, but none alone proves a stage transition.
Separate business-model evidence
SaaS needs retention/repeatable recurring revenue; marketplaces need liquidity/repeat on both sides; consumer apps need activation/cohort retention; hardware/deep tech need technical/manufacturing/commercialization gates. Stage evidence must fit the model.
Make stage determine the next question
Discovery asks “is this painful and reachable?” MVP asks “can we deliver core value?” Validation asks “will enough customers pay/repeat?” Scaling asks “can we add capital and capacity without breaking economics/quality?”
Match capital to the evidence gap
Friends/family, grants, customer revenue, angels, venture, strategic and debt each fit different risk/repayment profiles. Raising a “Seed” round does not make a business seed-ready if the evidence still belongs in discovery.
Use a stage-change memo
At each transition document evidence, metric baseline, unresolved risks, next 2–3 milestones and what you intentionally stop doing. This prevents the company from scaling costs ahead of proof.
Run the diligence stress test before investors do
Do not rehearse an answer. Rehearse the evidence. Give yourself a short diligence window and try to produce the underlying records without rebuilding the story from memory. A clean result is reproducible, tied to a source system or signed document, and consistent with the numbers elsewhere in the company.
- Idea/discovery: Put the underlying records on screen and prove this standard: Repeated customer/user evidence confirms painful problem, buyer/user and current alternative. If the evidence still looks like this weak state—Problem based on founder belief.—record the gap, name an owner and give it a due date instead of explaining it away.
- MVP: Put the underlying records on screen and prove this standard: Smallest usable product tests core value with target users and measurable success criteria. If the evidence still looks like this weak state—Product exists.—record the gap, name an owner and give it a due date instead of explaining it away.
- Revenue/validation: Put the underlying records on screen and prove this standard: Multiple customers pay for substantially repeatable offer; economics/retention beginning to form. If the evidence still looks like this weak state—One paid project called PMF.—record the gap, name an owner and give it a due date instead of explaining it away.
- Seed/PMF search: Put the underlying records on screen and prove this standard: Evidence shows growing repeatability, retention/value and a credible path to scalable acquisition/delivery. If the evidence still looks like this weak state—Round label determines stage.—record the gap, name an owner and give it a due date instead of explaining it away.
- Scaling: Put the underlying records on screen and prove this standard: Repeatable acquisition/delivery/retention economics support adding capital faster than complexity. If the evidence still looks like this weak state—Team/headcount or funding grew.—record the gap, name an owner and give it a due date instead of explaining it away.
Do the math investors will do
Stage gate rule: a label changes only when required evidence is achieved. Build a checklist with “required,” “supporting,” and “not sufficient alone.” Example: first paid pilot is supporting evidence for commercial validation; repeat paid use, acceptable delivery economics and renewal/expansion evidence may be required before claiming repeatability.
Build the evidence investors can verify
- Business-model-specific stage gate checklist
- Evidence links for each passed gate
- Unresolved-risk register
- Next-stage milestone plan
- Capital source matched to current risk
- Stage-change memo with baseline metrics and stop-doing list
Questions an investor may ask
- What evidence moved you from MVP to validation?
- Which stage claim depends on one customer or one cohort?
- What risk is still hypothesis?
- Are you hiring/scaling ahead of repeatability?
- What would have to be true before you call the company “scaling”?
30-day repair sprint
- Days 1–4: choose business-model-specific stage framework.
- Days 5–10: inventory evidence for every claimed gate.
- Days 11–15: downgrade unsupported labels without shame.
- Days 16–20: define next stage pass criteria.
- Days 21–25: align budget/hiring/capital with current stage.
- Days 26–30: publish stage-change memo and use it in board/investor reporting.
Research behind this guide
Use the primary and authoritative sources below to verify current rules, market conditions and technical guidance. Terms and regulations can change.